On March 25, 2021, the Court of Justice of the European Union published its judgments in the Lundbeck case. The CJEU dismissed the parties’ appeals in their entirety and upheld the General Court’s findings that Lundbeck and the generic manufacturers were potential competitors and that each of the patent settlement agreements entered into by the parties restricted competition “by object.” The CJEU’s legal analysis is largely based on its judgment from January 30, 2020 in the Paroxetine case. The CJEU nevertheless provides useful clarifications specific to the Lundbeck agreements and establishes a (novel) “specific duty of care” requiring companies to properly retain evidence, which may impact companies beyond the pharmaceutical sector. This article provides an overview of the CJEU’s analysis and sets out some practical implications for companies to consider.
Competition Policy International
EU Court of Justice Rules on Lundbeck Patent Settlement Agreements